The aim of the study is to evaluate the relationship between the adverse events and efficacy of @entity2857 in @entity1 with @entity1358 ( @entity1358 ), with a purpose to guide the judgment of efficacy in @entity2857 treatment.Eighty-three @entity1358 @entity1 who received @entity2857 therapy at northwest China were studied retrospectively. Univariate and multivariate analyses were performed to correlate @entity5 response, progression-free survival (PFS), and @entity1349 ( @entity1349 ) with adverse event types and grades.Among 83 @entity1 who underwent @entity2857 therapy, 2 cases (2.4%) had completed response (CR), 14 cases (16.9%) had partial response (PR), 57 cases (68.7%) had @entity66 ( @entity66 ), and 10 cases (12.0%) developed @entity74 ( @entity74 ). The median PFS and @entity1349 were 15.0 and 29.0 months, respectively. The most frequent grade 1 or 2 adverse events included @entity8566 (68.7%), @entity294 (54.2%), and @entity1665 (51.8%). The most common grade 3 or 4 adverse events were @entity8566 (6.0%), @entity101 (4.8%), and @entity294 (3.6%). The frequency and severity of adverse events correlated with @entity5 response rate (both with P < 0.05). Multivariate analysis showed the independent predictors of better PFS included @entity1910 (OR 0.307, 95%CI 0.148-0.636, P=0.001) and @entity294 (OR 0.391, 95%CI 0.169-0.783, P=0.008). Elevated transaminase was the independent predictor of poor PFS (OR 2.606, 95%CI 1.299-5.532, P=0.012). For @entity1349 , @entity1910 (OR 0.473, 95%CI 0.253-0.886, P=0.019) and @entity294 (OR 0.321, 95%CI 0.171-0.605, P=0.000) correlated with better @entity1349 . @entity2857 -related adverse events are associated with efficacy in @entity1 with @entity1358 from northwest China. @entity1910 and @entity294 are independent protective factors of both PFS and @entity1349 , and elevated transaminase is an independent risk factor of PFS. A large prospective study is warranted.

The Relationship Between the Adverse Events and Efficacy of @entity2857 in @entity1 With XXXX : A Multicenter Retrospective Study from Northwest China.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1665 :: ('MESH:D000505', 'Disease') :: ['alopecia'] @entity66 :: ('MESH:D004194', 'Disease') :: ['stable disease', 'SD'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity1910 :: ('MESH:D005076', 'Disease') :: ['rash', 'Rash'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity2857 :: ('MESH:C471405', 'Chemical') :: ['sorafenib', 'Sorafenib'] @entity1358 :: ('MESH:D002292', 'Disease') :: ['mRCC', 'metastatic renal cell carcinoma'] @entity74 :: ('MESH:D030342', 'Disease') :: ['PD', 'progressive disease'] @entity8566 :: ('MESH:D060831', 'Disease') :: ['hand-foot syndrome'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity1358 :: (MESH:D002292,Disease) :: ['Metastatic Renal Cell Carcinoma']
